Esperion Therapeutics, Inc. (ESPR)Healthcare | Drug Manufacturers - Specialty & Generic | Ann Arbor, United States | NasdaqGM
3.18 USD
After hours: 3.18 |
Hot Take ↕ | July 11, 2026, 6:54 a.m. EDT
The investment case for Esperion is currently broken by a perfect storm of deteriorating fundamentals and overwhelming speculative pessimism. While the company recently secured a merger with Essence Parent—a potential catalyst for survival—the financial reality is stark: the stock trades at a negative book value, generates negative free cash flow, and has suffered a catastrophic 89% decline over the last nine years. The recent approval of the merger offers a glimmer of hope, but the market has priced in significant distress, evidenced by the massive put-heavy options flow which suggests traders are betting hard against any recovery. With no dividend to provide income and a balance sheet showing debt significantly outweighing cash, the long-term outlook remains precarious until the merger closes and delivers tangible operational improvements. The statistical models show no directional bias, reflecting the uncertainty, but the fundamental damage is severe. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.463154 |
| AutoTheta | 0.721980 |
| AutoETS | 0.750954 |
| AutoARIMA | 0.773045 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 30% |
| H-stat | 1.20 |
| Ljung-Box p | 0.225 |
| Jarque-Bera p | 0.000 |
| Excess Kurtosis | 17.51 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Revenue per Share | 1.887 |
| Market Cap | 819,464,832 |
| Trailing P/E | Infinity |
| Forward P/E | 12.35 |
| Beta | 1.06 |
| Profit Margins | -1.77% |
| Website | https://www.esperion.com |
As of July 11, 2026, 6:54 a.m. EDT: Speculators are overwhelmingly bearish, positioning massive out-of-the-money put volume relative to calls across nearly all expirations. The open interest in puts is significantly higher than calls, with heavy concentration at strikes well below the current price, indicating a strong expectation of further downside or a 'long gamma' setup where sellers profit from volatility without needing a crash. Call activity is sparse and mostly centered at the money or slightly out, lacking the aggressive bullish positioning seen in the put book.
| Attribute | Value |
|---|---|
| 52 Week Change | 1.6949153 |
| Address1 | 3,891 Ranchero Drive |
| Address2 | Suite 150 |
| All Time High | 120.96 |
| All Time Low | 0.69 |
| Ask | 3.19 |
| Ask Size | 1,251 |
| Audit Risk | 10 |
| Average Daily Volume10 Day | 21,883,620 |
| Average Daily Volume3 Month | 15,613,259 |
| Average Volume | 15,613,259 |
| Average Volume10Days | 21,883,620 |
| Beta | 1.064 |
| Bid | 3.18 |
| Bid Size | 43 |
| Board Risk | 6 |
| Book Value | -1.196 |
| City | Ann Arbor |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 8 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 3.18 |
| Current Ratio | 1.53 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 3.19 |
| Day Low | 3.18 |
| Display Name | Esperion Therapeutics |
| Earnings Call Timestamp End | 1,778,155,200 |
| Earnings Call Timestamp Start | 1,778,155,200 |
| Earnings Timestamp | 1,778,184,000 |
| Earnings Timestamp End | 1,785,873,600 |
| Earnings Timestamp Start | 1,785,873,600 |
| Ebitda | 75,894,000 |
| Ebitda Margins | 0.18146 |
| Enterprise To Ebitda | 15.894 |
| Enterprise To Revenue | 2.884 |
| Enterprise Value | 1,206,282,624 |
| Eps Current Year | -0.21 |
| Eps Forward | 0.2575 |
| Eps Trailing Twelve Months | 0.0 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 3.0958 |
| Fifty Day Average Change | 0.084200144 |
| Fifty Day Average Change Percent | 0.027198186 |
| Fifty Two Week Change Percent | 169.49153 |
| Fifty Two Week High | 4.18 |
| Fifty Two Week High Change | -0.99999976 |
| Fifty Two Week High Change Percent | -0.2392344 |
| Fifty Two Week Low | 1.1 |
| Fifty Two Week Low Change | 2.08 |
| Fifty Two Week Low Change Percent | 1.890909 |
| Fifty Two Week Range | 1.1 - 4.18 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,372,253,400,000 |
| Float Shares | 234,219,304 |
| Forward Eps | 0.2575 |
| Forward P E | 12.349515 |
| Free Cashflow | -49,706,376 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 294 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | 0.5779 |
| Gross Profits | 241,702,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.0090499995 |
| Held Percent Institutions | 0.71294 |
| Implied Shares Outstanding | 257,693,347 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Industry Disp | Drug Manufacturers - Specialty & Generic |
| Industry Key | drug-manufacturers-specialty-generic |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Esperion Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C) in the United States. The company's marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia cardiovascular disease who require additional lowering of LDL-C. Its products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. It has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was formerly known as HDL Therapeutics, Inc. and changed its name to Esperion Therapeutics, Inc. in May 2008. The company was incorporated in 2008 and is headquartered in Ann Arbor, Michigan. |
| Long Name | Esperion Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 819,464,832 |
| Market State | POSTPOST |
| Max Age | 86,400 |
| Message Board Id | finmb_28236 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -7,423,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 822,041,776 |
| Number Of Analyst Opinions | 4 |
| Open | 3.18 |
| Operating Cashflow | -18,187,000 |
| Operating Margins | -0.082159996 |
| Overall Risk | 8 |
| Payout Ratio | 0.0 |
| Phone | 734 887 3903 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 3.18 |
| Post Market Time | 1,783,726,912 |
| Previous Close | 3.18 |
| Price Eps Current Year | -15.142858 |
| Price Hint | 4 |
| Price To Book | -2.658863 |
| Price To Sales Trailing12 Months | 1.9592985 |
| Profit Margins | -0.01775 |
| Quick Ratio | 0.961 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.0 |
| Regular Market Change Percent | 0.0 |
| Regular Market Day High | 3.19 |
| Regular Market Day Low | 3.18 |
| Regular Market Day Range | 3.18 - 3.19 |
| Regular Market Open | 3.18 |
| Regular Market Previous Close | 3.18 |
| Regular Market Price | 3.18 |
| Regular Market Time | 1,783,713,601 |
| Regular Market Volume | 59,090,465 |
| Return On Assets | 0.12044 |
| Revenue Growth | 0.232 |
| Revenue Per Share | 1.887 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 257,693,347 |
| Shares Percent Shares Out | 0.0675 |
| Shares Short | 17,401,689 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 18,714,926 |
| Short Name | Esperion Therapeutics, Inc. |
| Short Percent Of Float | 0.0687 |
| Short Ratio | 1.58 |
| Source Interval | 15 |
| State | MI |
| Symbol | ESPR |
| Target High Price | 3.28 |
| Target Low Price | 3.16 |
| Target Mean Price | 3.19 |
| Target Median Price | 3.16 |
| Total Cash | 156,158,000 |
| Total Cash Per Share | 0.607 |
| Total Debt | 543,806,976 |
| Total Revenue | 418,244,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | 0.0 |
| Trailing P E | Infinity |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 3.0548 |
| Two Hundred Day Average Change | 0.12520003 |
| Two Hundred Day Average Change Percent | 0.04098469 |
| Type Disp | Equity |
| Volume | 59,090,465 |
| Website | https://www.esperion.com |
| Zip | 48,108 |